Literature DB >> 24508523

Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells.

Tamaki Ishima1, Yuko Fujita1, Kenji Hashimoto2.   

Abstract

The sigma-1 receptor chaperone located in the endoplasmic reticulum (ER) may be implicated in the mechanistic action of some antidepressants. The present study was undertaken to examine whether new antidepressant drugs interact with the sigma-1 receptor chaperone. First, we examined the effects of selective serotonin reuptake inhibitors (SSRIs) (fluvoxamine, paroxetine, sertraline, citalopram and escitalopram), serotonin and noradrenaline reuptake inhibitors (SNRIs) (duloxetine, venlafaxine, milnacipran), and mirtazapine, a noradrenaline and specific serotonergic antidepressant (NaSSA), on [(3)H](+)-pentazocine binding to rat brain membranes. Then, we examined the effects of these drugs on nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. The order of potency for drugs at the sigma-1 receptor chaperone was as follows: fluvoxamine>sertraline>fluoxetine>escitalopram>citalopram>paroxetine>duoxetine. Venlafaxine, milnacipran, and mirtazapine showed very weak affinity for this chaperone. Furthermore, fluvoxamine, fluoxetine, escitalopram, and mirtazapine significantly potentiated NGF-induced neurite outgrowth in cell assays, and the effects of all these drugs, excluding mirtazapine, were antagonized by NE-100, a selective antagonist of the sigma-1 receptor chaperone. Moreover, the effects of fluvoxamine and fluoxetine on neurite outgrowth were also antagonized by sertraline, indicating that sertraline may be an antagonist at the sigma-1 receptor chaperone. The effect of mirtazapine on neurite outgrowth was antagonized by the selective 5-hydroxytryptamine1A receptor antagonist WAY-100635. These findings suggest that activation at the sigma-1 receptor chaperone may be involved in the action of some SSRIs, such as fluvoxamine, fluoxetine and escitalopram. In contrast, mirtazapine independently potentiated neurite outgrowth in PC12 cells, indicating that this beneficial effect may mediate its pharmacological effect.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressant; Mirtazapine; Neurite outgrowth; Selective serotonin reuptake inhibitor; Serotonin and noradrenaline reuptake inhibitor; Sigma-1 receptor chaperone

Mesh:

Substances:

Year:  2014        PMID: 24508523     DOI: 10.1016/j.ejphar.2014.01.064

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  29 in total

Review 1.  Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

Review 2.  Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

Authors:  Linda Nguyen; Brandon P Lucke-Wold; Shona Mookerjee; Nidhi Kaushal; Rae R Matsumoto
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; John A Schetz
Journal:  Neurochem Int       Date:  2017-02-08       Impact factor: 3.921

4.  Involvement of PI3K/Akt/FoxO3a and PKA/CREB Signaling Pathways in the Protective Effect of Fluoxetine Against Corticosterone-Induced Cytotoxicity in PC12 Cells.

Authors:  Bingqing Zeng; Yiwen Li; Bo Niu; Xinyi Wang; Yufang Cheng; Zhongzhen Zhou; Tingting You; Yonggang Liu; Haitao Wang; Jiangping Xu
Journal:  J Mol Neurosci       Date:  2016-07-13       Impact factor: 3.444

5.  Sigma-1 receptor ligands inhibit catecholamine secretion from adrenal chromaffin cells due to block of nicotinic acetylcholine receptors.

Authors:  Rebecca L Brindley; Mary Beth Bauer; Nolan D Hartley; Kyle J Horning; Kevin P M Currie
Journal:  J Neurochem       Date:  2017-09-19       Impact factor: 5.372

6.  Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.

Authors:  Eric J Lenze; Caline Mattar; Charles F Zorumski; Angela Stevens; Julie Schweiger; Ginger E Nicol; J Philip Miller; Lei Yang; Michael Yingling; Michael S Avidan; Angela M Reiersen
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

7.  Involvement of GABAA receptors in 5-HT1A and σ1 receptor synergism on prefrontal dopaminergic transmission under circulating neurosteroid deficiency.

Authors:  Yukio Ago; Shigeru Hasebe; Naoki Hiramatsu; Kazuya Mori; Yuji Watabe; Yusuke Onaka; Hitoshi Hashimoto; Kazuhiro Takuma; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2016-06-23       Impact factor: 4.530

8.  Propellanes as Rigid Scaffolds for the Stereodefined Attachment of σ-Pharmacophoric Structural Elements to Achieve σ Affinity.

Authors:  Héctor Torres-Gómez; Constantin Daniliuc; Dirk Schepmann; Erik Laurini; Sabrina Pricl; Bernhard Wünsch
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 9.  Sigmar1's Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology.

Authors:  Richa Aishwarya; Chowdhury S Abdullah; Mahboob Morshed; Naznin Sultana Remex; Md Shenuarin Bhuiyan
Journal:  Front Physiol       Date:  2021-07-07       Impact factor: 4.566

10.  Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole.

Authors:  Mikhail V Voronin; Yulia V Vakhitova; Inna P Tsypysheva; Dmitry O Tsypyshev; Inna V Rybina; Rustam D Kurbanov; Elena V Abramova; Sergei B Seredenin
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.